natgillin/translations-raw huggingface dataset:
The method of claim 19, wherein the HIV-1 titer in the subject infected with HIV-1is decreased after contacting the subject with the immunogenic composition. 
Uporaba u skladu s patentnim zahtjevom 1, naznačena time što so HIV titar kod subjekta inficiranog HIV-om smanjuje nakon kontaktiranja subjekta s izoliranim polipeptidom.
The antibody or antibodies for the use according to any one of claims 1-4, wherein the cancer is cancer of the head or neck. 
Antitijela za primjenu iz patentnog zahtjeva 8, gdje rak je rak glave ili vrata.
The method according to claim 1, wherein the Micafungin starting material and the aqueous solution in step b) comprises 2-30% v/v of a water miscible organic solvent. 
Postupak prema zahtjevu 1, naznačen time da vodena otopina sadrži otopljenu sol Micafungina u koraku a) i vodena otopina u koraku b) prema predmetnom postupku sadrži Metanol.
Citrate buffers are not preferred for basic buffered lozenges, for example lozenges having nicotine as the active agent, as they do not provide the optimal pH. 
Citratni puferi nisu poželjni za bazno puferirane tablete, na primer tablete koje imaju nikotin kao aktivno sredstvo, jer ne osiguravaju optimalnu pH.
applying a differential pressure of at least 0.5 bar to the mixture by compressed air, as a result of which the fluid portion of the mixture is forced through the filter and a filter cake containing cells remains in the filter housing, wherein the absolute pressure at the withdrawal point is at least 0.7 bar, and removal of the filtered fluid, 
Cc) - primjenu diferencijalnog tlaka od najmanje 0,5 bara na smjesu pomoću stlačenog zraka, što rezultira time da se tekući dio smjese potiskuje kroz filter i filtarski kolač koji sadrži stanice ostaje u kućištu filtra, pri čemu je apsolutni tlak na mjestu ekstrakcije najmanje 0,7 bara; d) -ekstrahiranje filtrirane tekućine.
A pharmaceutical composition characterized by comprising at least one of the antibodies or functional fragments of the antibodies according to (1) to (26). 
Farmaceutski pripravak karakteriziran time što sadrži najmanje jedno od monoklonskih antitijela ili njihovih funkcionalnih fragmenata sukladnih zahtjevima 1-15.
The term "salt(s)", as employed herein, denotes acidic and/or basic salts formed with inorganic and/or organic acids and bases. 
N(CHs),, imidazolil, iili N-morfolinil; i/ili farmaceutski prihvatljive soli, solvati, stereoizomeri i/ili hidrati ovog spoja. 5.
Id. No. 3. The pharmaceutical formulation of claims 1 to12, wherein the heavy chain of the Abeta antibody comprises the amino acid sequence of Seq. 
Farmaceutska formulacija prema zahtjevima od 1 do 12, naznačena time, da jaki lanac od Abeta-protutijela sadrži aminokiselinsku sekvencu od SEQ ID NO:10.
is a group optionally substituted selected from straight or branched (C1-C8) alkyl and (C3-C8) cycloalkyl; 
je izborno supstituirana skupina, koju se bira između nerazgranatog ili razgranatog (C1-C8) alkila i (C3-C8) cikloalkila;
a nucleotide sequence selected from among SEQ ID NOs: 1 - 54 (wherein uracil may be thymine), wherein 1 to 4 nucleotides are substituted, deleted, inserted or added; and 
nukleotidna sekvenca koja je odabrana od SEQ ID NO: 1 do SEQ ID NO:54 (pri čemu uracil može biti tiamin), gdje su od jednoga do četiri nukleotida zamijenjeni, odstranjeni ili umetnuti; i
An electrically heated smoking system and a solid aerosol-forming substrate according to any preceding claim, wherein during operation, the aerosol-forming substrate is partially contained within the electrically heated smoking system. 
Električno grijani sustav za pušenje u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se, tijekom rada, supstrat koji stvara aerosol dijelom nalazi u električno grijanom sustavu za pušenje.
The reaction is allowed to rise to room temperature with stirring overnight. 
Reakcijsku smjesu ostavi se preko noći da se zagrije do sobne temperatura, uz miješanje.
drying at 20 - 25 °C under a slight stream of nitrogen, 
- < sušenje na 20-25 "C u laganoj struji dušika,
• Ar1 is 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, or phenyl, each unsubstituted or substituted at a carbon ring member with one or two Ra moieties; 
• Ar1 je 2-piridil, 3-piridil, 4-piridil, 2-pirimidinil, 4-pirimidinil, 5-pirimidinil, ili fenil, svaki nesupstituiran ili supstituiran na ugljiku članu prstena sa jednom ili dvije Ra funkcionalne skupine;
The HDL-raising or HDL mimicking agent, in particular a CETP inhibitor/modulator for use in the treatment of cardiovascular disorder, wherein the subject treated has an improved response genotype rs 1967309. 
Dalcetrapib, naznačen time, da služi za uporabu u liječenju kardiovaskularnog poremećaja u ispitanika koji je identificiran kao da ima genotip poboljšanog odgovora na jednom ili više polimorfnih mjesta na ispitanikovom genu ADCY9.
When R13=hydrogen in formula XIII, then this position is protected prior to the coupling reaction and deprotected after the coupling reaction according to standard literature procedures with standard protection groups, e.g. 
Ako je R'* - vodik u formuli XIII tada je ta pozicija zaštićena prije vezne reakcije i deprotektirana nakon vezne reakcije u skladu sa standardnim postupcima iz literature sa standardnim zaštitnim grupama kao npr.
The composition for use according to any one of the preceding claims, wherein the method comprises administering a composition comprising 1-1000 µg of a bacterial IL-10 expression construct and 5-1000 µg D-mannose. 
Sastav za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time, da postupak obuhvaća primjenu sastava koji obuhvaća 1-1000 ug bakterijskog ekspresijskog konstrukta IL-10 i 5-1000 ug D-manoze.
A pharmaceutical composition according to claim 29, further comprising at least one additional therapeutic agent. 
Farmaceutski sastav prema patentnom zahtjevu 21, naznačen time, da nadalje sadrži barem jednu dodatnu terapeutski djelotvornu tvar.
The method of claim 17, wherein said buffering agent is a salt of an organic or inorganic acid. 
Postupak u skladu s patentnim zahtjevom 16, gdje navedeno pufersko sredstvo je sol organske ili anorganske kiseline.
The compound for use according to claim 13, wherein the leukemia is selected from acute lymphocytic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, myeloproliferative disorder/neoplasm and myelodysplastic syndrome. 
Tvar za uporabu u skladu s patentnim zahtjevom 13, pri čemu je leukemija odabrana između akutne limfocitne leukemije, kronične limfocitne leukemije, kronične mijeloične leukemije, mijeloproliferativnog poremećaja/neoplazme i mijelodisplastičnog sindroma.
A pharmaceutical composition for use in the method of claim 13, wherein the topical corticosteroids are administered in an initial treatment period in the method, with the topical corticosteroids completely stopped or withdrawn in a subsequent treatment period in the method or reduced by about 10%, about 20%, about 30%, about 40%, about 50%, or more as compared to the dose during the initial treatment period. 
Farmaceutski pripravak za primjenu u metodi prema zahtjevu 13, naznačen time, što se metoda sastoji od početnog razdoblja u kojem se primjenjuje antitijelo protiv humanog IL-4R ili njegov fragment koji se vezuje za antigen, nakon čega slijedi razdoblje u kojem se postepeno smanjuje doza topikalnih kortikosteroida, dok se nastavlja primjena antitijela protiv humanog IL-4R ili njegovog fragmenta koji se vezuje za antigen.
A method as claimed in claim 5 wherein the crumb has a water content from about 0.5% to about 0.6% by weight. 
Postupak prema zahtjevu 4, pri čemu mrvice imaju sadržaj vode od 0,5% do 0,6 tež. %.
Wind system (1) according to claim 1, characterised in that said recovering system (8) comprises at least one cylindrical pipe. 
Vjetreni sustav (1) prema zahtjevu 4, naznačen time da spomenuti sustavi koji pokreću spomenute budu piezoelektričnog tipa.
The method according to claim 1, wherein the rotational movement of the gas is produced by the inclination of the at least one nozzle and/or by the configuration of the supply line in the gas and sorbent injection region itself. 
Postupak prema Zahtjevu 1, »aznačen time, što se rotacijsko kretanje plina dodatno proizvodi nagibom mlaznica (2) i/ili oblikom linije za dopremanje u samom području za ubrizgavanje plina i sorbenta.
a container that contains a pharmaceutical composition containing a peptide according to any one of claims 1 to 4, the nucleic acid or the expression vector according to claim 5, a cell according to claim 7 or 8, or an activated cytotoxic T lymphocyte according to claim 11, in solution or in lyophilized form; and 
(a) Kutije koja sadrži farmaceutski sastav koji se sastoji od peptida u skladu s bilo kojim zahtjevom 1 - 4, nukleinske kiseline ili ekspresijskog vektora u skladu s patentnim zahtjevom 5, stanice u skladu s patentnim zahtjevom 7 ili 8, ili aktiviranog citotoksičnog T-limfocita u skladu s patentnim zahtjevom 11, u otopini ili liofiliziranom obliku; i
exposing a mouse according to any one of claims 1 to 10 to an antigen; allowing the mouse of (i) to develop an immune response to the antigen; and isolating from the mouse of (ii) an antibody that specifically recognizes the antigen, or isolating from the mouse of (ii) a cell comprising an immunoglobulin domain that specifically recognizes the antigen, or identifying in the mouse of (ii) a nucleic acid sequence encoding a heavy and/or light chain variable domain that binds to the antigen. 
Postupak za izradu antitijela u mišu koji se sastoji od a) b) izlaganja miša prema bilo kojem zahtjevu od 1 do 10ili 17 antigenu; puštanja miša da razvije imunološki odgovor na antigen; i izoliranja iz miša (b) antitijela koje specifično prepoznaje antigen ili izoliranja iz miša (b) stanice koja se sastoji od imunoglobulinske domene koja posebno prepoznaje antigen, pri čemu antitijelo sadrži lanac dobiven iz humanog VA segmenta gena, humanog JA segmenta gena i mišjeg CK gena.
One aspect of the invention relates to a process for preparing a crystalline freebase (Form III) of the compound of formula I: 
PATENTNI ZAHTJEVI M» Postupak za pripravu kristalne slobodne baze (Oblik III) spoja formule I:
The compound of formula (IV) may be obtained from a compound of formula (VIII): 
Spoj formule (IV) može se dobiti iz spoja formule (VIII):
A pure culture of the strain called AH2 of the Bacillus velezensis species, as well as its mutants, characterized by having a high antifungal activity and particularly against phytopathogenic fungi given its capacity to produce antagonist substances, as well as a good capacity to stimulate plant growth, the strain being capable of solubilizing phosphates, producing indole-3-acetic acid and siderophores, as well as capable of growing in 1-aminocyclopropane-1-carboxylic acid (ACC) as a sole nitrogen source, said strain having been deposited in the Spanish Type Culture Collection (CECT) with the number CECT-7221. 
HR P20141044 T1 PATENTNI ZAHTJEVI Čista kultura soja nazvanog AH2 vrste Bacillus velezensis, kao i njegovi mutanti, naznačena time što imaju visoku antifungalnu aktivnost i naročito protiv fitopatogenih gljivica s obzirom na njihov kapacitet za proizvodnju antagonističkih supstanci, kao 1 dobar kapacitet za stimuliranje rasta biljaka, koji soj je sposoban otapati fosfate, proizvoditi indol-3-octenu kiselinu i siderofore, kao i sposobnost stvaranja 1-aminociklopropan-1-karboksilne kiseline (ACC) kao isključivog izvora dušika, koji soj je deponiran kod Spanish Type Culture Collection (CECT) pod brojem CECT-7221.
A composition of matter according to claim 3 which is a foodstuff comprising 5-D-fructose dehydrogenase wherein the 5-D-fructose dehydrogenase has been added to the foodstuff at the production stage thereof for the purpose of developing its effect after ingestion of the foodstuff. 
-D-fruktoza dehidrogenaza za uporabu prema zahtjevu 11, naznačena time, da je navedeni sastav tvari u obliku jedinične doze, a navedena jedinična doza sadrži između 10 i 5 milijuna jedinica aktivnosti 5-D-fruktoze dehidrogenaze.
A composition suitable for control of diseases caused by phytopathogens comprising (A) a compound of formula I wherein R1 is difluoromethyl or trifluoromethyl and X is chloro, fluoro or bromo; and (B) at least one compound selected from compounds known for their fungicidal activity; and a method of controlling diseases on useful plants, especially rust diseases on soybean plants. 
Pripravak pogodan za kontrolu bolesti uzrokovanih fitopatogenima koji se sastoji od: (A) spoja formule (I) naznačen time da R1 je difluorometil ili trifluorometil i X je kloro, fluoro ili bromo; i (B) spoj mandipropamid.
Separately, Tween 80 was dissolved in 250 mL water with heating at 70° C. Glyceryl monostearate was added to the Tween 80 solution at 70° C. and mixed. 
Odvojeno, Tween 80 se otopi u 250 ml vode uz zagrijavanje na 70 *C. Doda se gliceril monostearat u otopinu Tween-a 80 na 70 "C 1 miješa se.
optionally in the form of the acid addition salts thereof, preferably in the form of the para-toluenesulphonic acid salt thereof, characterised in that in a first step a diamine of formula 2 
Postupak priprave spoja formule l Ka po izboru u obliku njegovih kiselinskih adicijskih soli, naznačen time, da u prvom koraku diamin formule 2 1
The pharmaceutical composition of claim 9 wherein the film coat comprises a film-forming agent, a plasticizer, a glidant and optionally one or more pigments. 
Farmaceutski pripravak u skladu sa zahtjevom 4, naznačen time, da film obloga sadrži film-formirajuće sredstvo, plastifikator, sredstvo za klizavost i po izboru jedan ili više pigmenata.
capturing the conductor on the conductor holder end of the insulator stack, 
zahvaćanje vodiča na držaču vodiča na kraju od izolacijske naslage,
■ The diluent should have a reactive group that allows it to be incorporated into the dry film. 
"Sredstvo za razrjeđivanje mora imati reaktivnu skupinu koja omogućuje njegovu ugradnju u suhi film.
There is also a downstream peak with a mean diameter of 53.7nm, representing the remaining 0.01% of particles. 
Postoji također daljnji pik sa srednjim promjerom od 53,7nm, predstavljajući preostalih 0,01% čestica.
Preferably, the sidewall(s) terminate in a curled or slightly bend edge portion that is adapted to grip around corresponding edges of the inner part so as to retain the inner part. 
Poželjno je da bočne stijenke završavaju s predjelom ruba koji je zafrkan ili blago savijen i koji je prilagođen da zahvaća oko odgovarajućih rubova unutarnjeg dijela, tako da se drži unutarnji dio.
Specifically, the compound is administered to the patient in a therapeutically effective amount to increase the insuling expression or level, in particular to treat hypoinsulinemia, preferably by systemic or local administration. 
Spoj artemizinina namijenjen upotrebi u skladu sa zahtjevom 1 ili 2, naznačen time što se spoj primjenjuje na pacijentu u terapijski djelotvornoj količini za liječenje hipoinzulinemije, po mogućnosti sistemnom ili lokalnom primjenom.
The double stranded RNAi agent of claim 43, wherein the RNAi agent is conjugated to the ligand as shown in the following schematic 
Dvolančano RNAi sredstvo prema zahtjevu 6, naznačeno time da je RNA: sredstvo konjugirano na ligand kako je prikazano u slijedećoj shemi
Thus, one embodiment of the invention relates to a large-scale process for preparing an alpha-aminoboronic ester compound of formula (VIIa) or (VIIb): 
Postupak koji koristi najmanje pet mola najmanje jednog početnog materijala za pripremu spoja ostera aminoorganoborne kiseline formule (VIIa) ili (VIIb):
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) mandipropamid. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1Hpirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, le kao komponentu (B) fluopiram.
A method of modulating the activity of adrenomedullin in a subject in need of regulation of fluid balance comprising administering an anti-adrenomedullin (ADM) antibody or an anti-ADM antibody fragment, wherein said antibody or antibody fragment binds to a region of at least 4 amino acids within the sequence of aa 1-42 of mature human ADM: YRQSMNNFQGLRSFGCRFGTCTVQKLAHQIYQFTDKDKDNVA (SEQ ID NO: 24), and wherein said antibody or fragment does not bind to the C-terminal portion of ADM (aa 43-52 of ADM (SEQ ID NO: 25)), and 
Protutijelo protiv adrenomedulina (ADM) ili fragment protutijela protiv ADM koji se veže na adrenomedulin ili okosnica ne-Ig protiv ADM koja se veže na adrenomedulin, naznačeni time što su namijenjeni upotrebi u terapiji akutne bolesti ili akutnog stanja kod pacijenta koji boluje od neravnoteže tekućina, te gdje navedeno protutijelo ili fragment protutijela ili okosnica ne-Ig koja se vežu na područje od najmanje 4 aminokiseline unutar slijeda aa 1-21 zrelog ljudskog ADM:
The ability to reactivate the apoptotic process in cancerous cells is of major therapeutic interest in the treatment of cancers, auto-immune diseases and diseases of the immune system. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 13, naznačen time, da se koristi za liječenje karcinoma, autoimunih bolesti 1 bolesti imunološkog sustava.
means for broadcasting, over the first (39) and the second (40) communication data link, at a first time interval, a first identification message carrying a third code identifying the first communication service provider network (22); and 
- < Sredstva konfigurirana za emitiranje, putem prve (39) 1 druge (40) komunikacijske podatkovne veze, u trećem vremenskom intervalu, treća identifikacijska poruka nosi peti kod identificirajući mrežu pružatelja prve komunikacijske usluge (22); 1
The method of claim 1, wherein the 4-1BB costimulatory signaling region comprises the amino acid sequence of SEQ ID NO:23. 
(i) - kostimulatorno signalno područje 4-1 BB sadrži aminokiselinsku sekvencu naznačenu u SEQ ID NO: 23;
wherein, as a prerequisite of the steps f)-i), a training set of euploid blood samples is subjected to essentially the same procedures consisting of steps a)-e) above and then the following steps are performed: 
usporedba vrijednosti iz rezultata s najmanje jednom graničnom vrijednosti da bi se odredilo da li aneuploidija postoji na kromosomu od interesa; pri čemu se, kao preduvjet iz koraka f)-i), komplet za obuku uzoraka krvi za euploidiju izlaže u osnovi istim postupcima koji sadrže korake a)-e) iznad i zatim se izvode slijedeći koraci:
The pharmaceutical composition of claim 9, further comprising one or more additional therapeutic agents selected from the group consisting of an inhibitor of HMG-CoA reductase, niacin, a fibrate, 22-hydroxycholesterol, ezetimibe plus simvastatin, a statin with a bile resin, niacin plus a statin, niacin plus an omega-3-fatty acid ethyl ester, a statin, an anti-hANGPTL4 antibody and an anti-PCSK9 antibody. 
Farmaceutski pripravak prema patentnom zahtjevu 9, koji dodatno sadrži jedno ili više dodatnih terapijskih sredstava odabranih iz skupine koja se sastoji od inhibitora HMG-CoA reduktaze, niacina, fibrata, 22-hidroksikolesterola, ezetimiba plus simvastatina, statina sa žučnom smolom, niacina plus statina, niacina plus etilnog estera omega-3 masne kiseline, statina, anti-hANGPTL4 antitijela i anti-PCSK9 antitijela.
Conservative amino acid substitutions of IL-18BP polypeptides or proteins or viral IL-18BPs, may include synonymous amino acids within a group which have sufficiently similar physicochemical properties that substitution between members of the group will preserve the biological function of the molecule (Grantham, 1974). 
Konzervativne supstitucije aminokiselina IL-18BP polipeptida ili proteina lii viralnih IL-18BP-a, mogu uključivati sinonimne supstitucije aminokiselina unutar grupe s dovoljno sličnim fizikalno-kemijskim svojstvima, tako da substitucijom između članova grupe biološka funkcija molekule ostaje sačuvana (Grantham, 1974).
X- [(Pro)n-His-Pro-His-Ala-Arg-Ile-Lys]m- Y (S 1) wherein X is H, or an acetyl group or any natural amino acid or sequence of amino acids provided with a free or at least acetyl-derivatized NH2 group; Y is an OH group or an NH2 group; "n" is an integer from 1 to 10 and "m" is an integer from 1 to 3; and wherein the amino acid sequence of the peptide-derived molecule is selected from the group consisting of: 
X- [(Pro)n-His-Pro-His-Ala-Arg-Ile-Lys]m- Y (S 1) naznačena time da X je H, ili acetil grupa ili bilo koja prirodna aminokiselina ili sekvenca aminokiselina koja ima slobodnu ili barem acetil-derivatiziranu NH2 skupinu; Y je skupina OH ili NH2 skupina; "n" je cijeli broj od 1 do 10 i "m" je cijeli broj od 1 do 3; i pri čemu se aminokiselinska sekvenca molekule izvedene iz peptida bira iz skupine koja se sastoji od:
The invention also consists in the provision of a method for treating festering wounds, trophic ulcers and burns, infiltrations with marked necrotic and exudative components by applying the antimicrobial composition of the present invention topically to the surface of a wound. 
Uporaba sastava prema zahtjevu 1 ili zahtjevu 2, naznačena time, da se koristi u proizvodnji lijeka za liječenje rana, trofičkih čireva i opeklina, infiltracija s naznačenim nekrotičkim i eksudativnim komponentama.
Examples of diseases where an A2A-receptor is implicated are Parkinson's Disease (PD), Alzheimer's Disease, Huntington's disease, epilepsia, cerebral ischemia, haemorrhagic stroke, neonatal ischemia and hypoxia, subarachnoid haemorrhage, traumatic brain injury, brain damage following cardiac arrest, and for the treatment of depression and psychosis disorders. 
Primjeri oboljenja, gdje su A2,-receptori implicirani, su Parkinsonova bolest (PD), Alzheimerova bolest, Huntingtonova bolest, epilepsija, cerebralna ishemija, moždani udar, neonatalna ishemija i hipoksija, subarahnoidno krvarenje, traumatsko oštećenje mozga, moždano oštećenje kao posljedica srčanog udara, te za tretman depresije u psihotičnih poremećaja.
This means that single bonding spots or bonding areas are separated in the horizontal direction or that a group of such bonding spots or bonding areas are arranged side-by-side in the horizontal or circumferential direction. 
To znači da su pojedinačne točke spajanja ili područja spajanja raspoređeni u horizontalnom ili u vertikalnom smjeru ili da je načinjena skupina od takvih točki spajanja ili područja spajanja koji su, na primjer, raspoređeni u vertikalnom smjeru i da su takve skupine tada raspoređene jedna uz drugu u horizontalnom ili u obodnom smjeru.
The food composition according to the claim 9, which is a water-in-oil emulsion. 
Sastav hrane prema zahtjevu 12, naznačen time da je emulzija voda-u-ulju.
An agent as claimed in any of claims 1-2 wherein the agent is an inhibitor of the binding properties of tenascin-C, or wherein the agent is a competitive binding inhibitor of tenascin-C. 
Sredstvo prema bilo kojem zahtjevu od 1-2 naznačeno time da je sredstvo inhibitor svojstava vezanja za tenascin-C, ili pri čemu je sredstvo konkurentni inhibitor vezanja za tenasein-C.
Crystalline Form I of a compound of formula characterized by an X-ray powder diffraction pattern comprising 2θ angle values of about 4.9; about 8.5; about 9.1; about 9.6; about 10.3; about 11.1; about 14.5; about 17.0; about 18.2; about 19.3. 
PATENTNI ZAHTJEVI L m ll. Kristalna Forma I spoja formule naznačena time što profil difrakcije X zraka u praškastom uzorku obuhvaća vrijednosti 20 kutova od oko 4.9; oko 8.5; oko 9.1; oko 10.3; oko 11.1; oko 14.5; oko 17.0; oko 18.2; oko 19.3.
The tubes 34 and 40 are connected with the aid of any connection which is known in the prior art, in this case a screw thread connection which is denoted overall by 39. 
Cijevi 34 i 40 su spojene pomoću bilo kakvog spoja koji je poznat u stanju tchnikc, u ovom slučaju pomoću spoja vijčanim navojem, koji je sveukupno označen s 39.